Results
of the PROGNOSIS1,2 study presented at the 20th World Congress on
Controversies in Obstetrics, Gynecology & Infertility in Paris, demonstrate
the prognostic value of the Elecsys® preeclampsia test from Roche to predict
the absence of preeclampsia for one week and the development of preeclampsia
within the subsequent four weeks.
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
- See more at:
http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324. - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324. - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324. - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324. - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
Results of the PROGNOSIS1,2
study presented at the 20th World Congress on Controversies in
Obstetrics, Gynecology & Infertility in Paris, demonstrate the
prognostic value of the Elecsys® preeclampsia test from Roche to predict
the absence of preeclampsia for one week and the development of
preeclampsia within the subsequent four weeks.
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
“Results from the PROGNOSIS study mark a significant step forward in the prediction of preeclampsia,” said Prof Harald Zeisler, Department of Obstetrics and Gynecology at Medical University Vienna, Austria. “The Elecsys preeclampsia test allows physicians to predict the short term absence and manifestation of preeclampsia. Its application in clinical practice has the potential to reduce fetal and maternal morbidity and mortality as well as to avoid unnecessary hospitalizations.”
Preeclampsia occurs in approximately 1 in 20 pregnancies and is the second most common cause of maternal death.8 The disease can be life-threatening for mother and baby, especially if diagnosed late, and is an indication for immediate preterm delivery when acute. The majority of cases develop in healthy women bearing their first child. Medical conditions such as chronic hypertension, diabetes and renal disease are associated with an increased risk of developing preeclampsia.
“We are pleased to introduce a new and reliable approach to predicting which woman at risk will develop preeclampsia within short-term, making a true diffence to the management of this serious condition”, said Roland Diggelmann, COO of Roche Diagnostics. “The new data allows us to set new standard in prenatal care, avoid unnecessary hospitalization and anxiety for the mother and her family. This is yet another testament to our commitment in women’s health.”
References
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
3) National Institute for Health and Clinical Excellence (NICE) (2011). Hypertension in pregnancy. NICE clinical guideline 107, London: RCOG Press.
4) ACOG Task Force on Hypertension in Pregnancy (2013). Hypertension in Pregnancy. Obstet Gynecol. 122, 1122-1131.
5) DGGG (2014). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. [http://www.awmf.org/uploads/tx_szleitlinien/015018l_S1_Diagnostik_Therapie_hypertensiver_
Schwangerschaftserkrankungen_2014-01.pdf]
6) Rana, S., et al. (2012) Circulation 125:911-9.
7) Elecsys® sFlt-1 and Elecsys® PlGF package inserts (Nov 2014). Roche Diagnostics Documentation, Basel.
8) Chaiworapongsa, T. et al. (2014). Nat Rev Nephrol 10, 466–480 - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
“Results from the PROGNOSIS study mark a significant step forward in the prediction of preeclampsia,” said Prof Harald Zeisler, Department of Obstetrics and Gynecology at Medical University Vienna, Austria. “The Elecsys preeclampsia test allows physicians to predict the short term absence and manifestation of preeclampsia. Its application in clinical practice has the potential to reduce fetal and maternal morbidity and mortality as well as to avoid unnecessary hospitalizations.”
Preeclampsia occurs in approximately 1 in 20 pregnancies and is the second most common cause of maternal death.8 The disease can be life-threatening for mother and baby, especially if diagnosed late, and is an indication for immediate preterm delivery when acute. The majority of cases develop in healthy women bearing their first child. Medical conditions such as chronic hypertension, diabetes and renal disease are associated with an increased risk of developing preeclampsia.
“We are pleased to introduce a new and reliable approach to predicting which woman at risk will develop preeclampsia within short-term, making a true diffence to the management of this serious condition”, said Roland Diggelmann, COO of Roche Diagnostics. “The new data allows us to set new standard in prenatal care, avoid unnecessary hospitalization and anxiety for the mother and her family. This is yet another testament to our commitment in women’s health.”
References
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
3) National Institute for Health and Clinical Excellence (NICE) (2011). Hypertension in pregnancy. NICE clinical guideline 107, London: RCOG Press.
4) ACOG Task Force on Hypertension in Pregnancy (2013). Hypertension in Pregnancy. Obstet Gynecol. 122, 1122-1131.
5) DGGG (2014). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. [http://www.awmf.org/uploads/tx_szleitlinien/015018l_S1_Diagnostik_Therapie_hypertensiver_
Schwangerschaftserkrankungen_2014-01.pdf]
6) Rana, S., et al. (2012) Circulation 125:911-9.
7) Elecsys® sFlt-1 and Elecsys® PlGF package inserts (Nov 2014). Roche Diagnostics Documentation, Basel.
8) Chaiworapongsa, T. et al. (2014). Nat Rev Nephrol 10, 466–480 - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
Results of the PROGNOSIS1,2
study presented at the 20th World Congress on Controversies in
Obstetrics, Gynecology & Infertility in Paris, demonstrate the
prognostic value of the Elecsys® preeclampsia test from Roche to predict
the absence of preeclampsia for one week and the development of
preeclampsia within the subsequent four weeks.
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
“Results from the PROGNOSIS study mark a significant step forward in the prediction of preeclampsia,” said Prof Harald Zeisler, Department of Obstetrics and Gynecology at Medical University Vienna, Austria. “The Elecsys preeclampsia test allows physicians to predict the short term absence and manifestation of preeclampsia. Its application in clinical practice has the potential to reduce fetal and maternal morbidity and mortality as well as to avoid unnecessary hospitalizations.”
Preeclampsia occurs in approximately 1 in 20 pregnancies and is the second most common cause of maternal death.8 The disease can be life-threatening for mother and baby, especially if diagnosed late, and is an indication for immediate preterm delivery when acute. The majority of cases develop in healthy women bearing their first child. Medical conditions such as chronic hypertension, diabetes and renal disease are associated with an increased risk of developing preeclampsia.
“We are pleased to introduce a new and reliable approach to predicting which woman at risk will develop preeclampsia within short-term, making a true diffence to the management of this serious condition”, said Roland Diggelmann, COO of Roche Diagnostics. “The new data allows us to set new standard in prenatal care, avoid unnecessary hospitalization and anxiety for the mother and her family. This is yet another testament to our commitment in women’s health.”
References
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
3) National Institute for Health and Clinical Excellence (NICE) (2011). Hypertension in pregnancy. NICE clinical guideline 107, London: RCOG Press.
4) ACOG Task Force on Hypertension in Pregnancy (2013). Hypertension in Pregnancy. Obstet Gynecol. 122, 1122-1131.
5) DGGG (2014). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. [http://www.awmf.org/uploads/tx_szleitlinien/015018l_S1_Diagnostik_Therapie_hypertensiver_
Schwangerschaftserkrankungen_2014-01.pdf]
6) Rana, S., et al. (2012) Circulation 125:911-9.
7) Elecsys® sFlt-1 and Elecsys® PlGF package inserts (Nov 2014). Roche Diagnostics Documentation, Basel.
8) Chaiworapongsa, T. et al. (2014). Nat Rev Nephrol 10, 466–480 - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
“Results from the PROGNOSIS study mark a significant step forward in the prediction of preeclampsia,” said Prof Harald Zeisler, Department of Obstetrics and Gynecology at Medical University Vienna, Austria. “The Elecsys preeclampsia test allows physicians to predict the short term absence and manifestation of preeclampsia. Its application in clinical practice has the potential to reduce fetal and maternal morbidity and mortality as well as to avoid unnecessary hospitalizations.”
Preeclampsia occurs in approximately 1 in 20 pregnancies and is the second most common cause of maternal death.8 The disease can be life-threatening for mother and baby, especially if diagnosed late, and is an indication for immediate preterm delivery when acute. The majority of cases develop in healthy women bearing their first child. Medical conditions such as chronic hypertension, diabetes and renal disease are associated with an increased risk of developing preeclampsia.
“We are pleased to introduce a new and reliable approach to predicting which woman at risk will develop preeclampsia within short-term, making a true diffence to the management of this serious condition”, said Roland Diggelmann, COO of Roche Diagnostics. “The new data allows us to set new standard in prenatal care, avoid unnecessary hospitalization and anxiety for the mother and her family. This is yet another testament to our commitment in women’s health.”
References
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
3) National Institute for Health and Clinical Excellence (NICE) (2011). Hypertension in pregnancy. NICE clinical guideline 107, London: RCOG Press.
4) ACOG Task Force on Hypertension in Pregnancy (2013). Hypertension in Pregnancy. Obstet Gynecol. 122, 1122-1131.
5) DGGG (2014). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. [http://www.awmf.org/uploads/tx_szleitlinien/015018l_S1_Diagnostik_Therapie_hypertensiver_
Schwangerschaftserkrankungen_2014-01.pdf]
6) Rana, S., et al. (2012) Circulation 125:911-9.
7) Elecsys® sFlt-1 and Elecsys® PlGF package inserts (Nov 2014). Roche Diagnostics Documentation, Basel.
8) Chaiworapongsa, T. et al. (2014). Nat Rev Nephrol 10, 466–480 - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
Results of the PROGNOSIS1,2
study presented at the 20th World Congress on Controversies in
Obstetrics, Gynecology & Infertility in Paris, demonstrate the
prognostic value of the Elecsys® preeclampsia test from Roche to predict
the absence of preeclampsia for one week and the development of
preeclampsia within the subsequent four weeks.
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
“Results from the PROGNOSIS study mark a significant step forward in the prediction of preeclampsia,” said Prof Harald Zeisler, Department of Obstetrics and Gynecology at Medical University Vienna, Austria. “The Elecsys preeclampsia test allows physicians to predict the short term absence and manifestation of preeclampsia. Its application in clinical practice has the potential to reduce fetal and maternal morbidity and mortality as well as to avoid unnecessary hospitalizations.”
Preeclampsia occurs in approximately 1 in 20 pregnancies and is the second most common cause of maternal death.8 The disease can be life-threatening for mother and baby, especially if diagnosed late, and is an indication for immediate preterm delivery when acute. The majority of cases develop in healthy women bearing their first child. Medical conditions such as chronic hypertension, diabetes and renal disease are associated with an increased risk of developing preeclampsia.
“We are pleased to introduce a new and reliable approach to predicting which woman at risk will develop preeclampsia within short-term, making a true diffence to the management of this serious condition”, said Roland Diggelmann, COO of Roche Diagnostics. “The new data allows us to set new standard in prenatal care, avoid unnecessary hospitalization and anxiety for the mother and her family. This is yet another testament to our commitment in women’s health.”
References
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
3) National Institute for Health and Clinical Excellence (NICE) (2011). Hypertension in pregnancy. NICE clinical guideline 107, London: RCOG Press.
4) ACOG Task Force on Hypertension in Pregnancy (2013). Hypertension in Pregnancy. Obstet Gynecol. 122, 1122-1131.
5) DGGG (2014). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. [http://www.awmf.org/uploads/tx_szleitlinien/015018l_S1_Diagnostik_Therapie_hypertensiver_
Schwangerschaftserkrankungen_2014-01.pdf]
6) Rana, S., et al. (2012) Circulation 125:911-9.
7) Elecsys® sFlt-1 and Elecsys® PlGF package inserts (Nov 2014). Roche Diagnostics Documentation, Basel.
8) Chaiworapongsa, T. et al. (2014). Nat Rev Nephrol 10, 466–480 - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care.
Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria).3,4.5 Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.6
The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term7, confidently focus on those women at high risk of preeclampsia.
“Results from the PROGNOSIS study mark a significant step forward in the prediction of preeclampsia,” said Prof Harald Zeisler, Department of Obstetrics and Gynecology at Medical University Vienna, Austria. “The Elecsys preeclampsia test allows physicians to predict the short term absence and manifestation of preeclampsia. Its application in clinical practice has the potential to reduce fetal and maternal morbidity and mortality as well as to avoid unnecessary hospitalizations.”
Preeclampsia occurs in approximately 1 in 20 pregnancies and is the second most common cause of maternal death.8 The disease can be life-threatening for mother and baby, especially if diagnosed late, and is an indication for immediate preterm delivery when acute. The majority of cases develop in healthy women bearing their first child. Medical conditions such as chronic hypertension, diabetes and renal disease are associated with an increased risk of developing preeclampsia.
“We are pleased to introduce a new and reliable approach to predicting which woman at risk will develop preeclampsia within short-term, making a true diffence to the management of this serious condition”, said Roland Diggelmann, COO of Roche Diagnostics. “The new data allows us to set new standard in prenatal care, avoid unnecessary hospitalization and anxiety for the mother and her family. This is yet another testament to our commitment in women’s health.”
References
1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study
2) Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324.
3) National Institute for Health and Clinical Excellence (NICE) (2011). Hypertension in pregnancy. NICE clinical guideline 107, London: RCOG Press.
4) ACOG Task Force on Hypertension in Pregnancy (2013). Hypertension in Pregnancy. Obstet Gynecol. 122, 1122-1131.
5) DGGG (2014). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. [http://www.awmf.org/uploads/tx_szleitlinien/015018l_S1_Diagnostik_Therapie_hypertensiver_
Schwangerschaftserkrankungen_2014-01.pdf]
6) Rana, S., et al. (2012) Circulation 125:911-9.
7) Elecsys® sFlt-1 and Elecsys® PlGF package inserts (Nov 2014). Roche Diagnostics Documentation, Basel.
8) Chaiworapongsa, T. et al. (2014). Nat Rev Nephrol 10, 466–480 - See more at: http://www.selectscience.net/product-news/roches-preeclampsia-test-helps-to-predict-this-life-threatening-condition-in-pregnant-women-at-risk/?artID=35800#sthash.oYpQJsdP.dpuf
No comments:
Post a Comment